Critical analysis of antibacterial agents in clinical development

Nature Reviews Microbiology

Volumn 18, Issue 5, 2020, Pages 286-298

  Theuretzbacher, Ursula ^a   Bush, Karen ^b   Harbarth, Stephan ^c   Paul, Mical ^d   Rex, John H ^e   Tacconelli, Evelina ^f   Thwaites, Guy E ^g,h  

^a Center For Anti Infective Agents Vienna   (Austria)

^b INDIANA UNIVERSITY   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e F2G LTD   (United Kingdom)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

^g OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; BOS 228; CEFEPIME; CEFIDEROCOL; CEFPODOXIME; CEFTIBUTEN; CILASTATIN; CILASTATIN SODIUM PLUS IMIPENEM PLUS RELEBACTAM; CONTEZOLID; CONTEZOLID ACEFOSAMIL; DELAFLOXACIN; DURLOBACTAM; ENMETAZOBACTAM; ERAVACYCLINE; GEPOTIDACIN; IMIPENEM; LEFAMULIN; MEROPENEM; NACUBACTAM; NAFITHROMYCIN; OMADACYCLINE; PLAZOMICIN; PROBENECID; RELEBACTAM; SULBACTAM; SULOPENEM; SULOPENEM ETZADROXIL; TANIBORBACTAM; TNP 2092; VABORBACTAM; ZIDEBACTAM; ZOLIFLODACIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIAL CELL; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SAFETY; ENTEROBACTERALES; ENZYME INHIBITION; EXTENSIVE DRUG RESISTANCE; GRAM NEGATIVE BACTERIUM; NONHUMAN; PAN DRUG RESISTANCE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; WORLD HEALTH ORGANIZATION; ACINETOBACTER INFECTION; DRUG DEVELOPMENT; DRUG EFFECT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG DEVELOPMENT; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; PSEUDOMONAS; PSEUDOMONAS INFECTIONS;

EID: 85081665890     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/s41579-020-0340-0     Document Type: Review

References (123)

1. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018). This WHO list prioritizes target pathogens for antibacterial drug research and discovery with a global perspective.
2. Theuretzbacher, U. et al. Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect. Dis. 19, e40–e50 (2019).
3. World Health Organization. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf (WHO, 2019).This WHO report presents the updated analysis of the global clinical pipeline including drugs against tuberculosis.
4. Theuretzbacher, U. Antibiotic innovation for future public health needs. Clin. Microbiol. Infect. 23, 713–717 (2017).
5. Theuretzbacher, U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr. Opin. Microbiol. 39, 106–112 (2017).
6. Theuretzbacher, U. & Piddock, L. J. V. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe 26, 61–72 (2019).
7. Rex, J. H., Fernandez Lynch, H., Cohen, I. G., Darrow, J. J. & Outterson, K. Designing development programs for non-traditional antibacterial agents. Nat. Commun. 10, 3416–3416 (2019).
8. J Libardo, M. D., Boshoff, H. I. & Barry, C. E. III. The present state of the tuberculosis drug development pipeline. Curr. Opin. Pharmacol. 42, 81–94 (2018).
9. World Health Organization. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/en/ (WHO, 2019).
10. Xie, R., Zhang, X. D., Zhao, Q., Peng, B. & Zheng, J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg. Microbes Infect. 7, 31 (2018).
11. Wright, M. S. et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. m Bio 5, e00963-13 (2014). Acinetobacter shows widespread genetic variation among strains, a high variability in antibiotic resistance determinants and dynamic genomic change over short evolutionary time spans.
12. Asif, M., Alvi, I. A. & Rehman, S. U. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug. Resist. 11, 1249–1260 (2018).
13. Tuan Anh, N. et al. Molecular epidemiology and antimicrobial resistance phenotypes of Acinetobacter baumannii isolated from patients in three hospitals in southern Vietnam. J. Med. Microbiol. 66, 46–53 (2017).
14. Castanheira, M., Deshpande, L. M., Costello, A., Davies, T. A. & Jones, R. N. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J. Antimicrob. Chemother. 69, 1804–1814 (2014).
15. Cabot, G. et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob. Agents Chemother. 55, 1906–1911 (2011).
16. del Barrio-Tofiño, E. et al. Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob. Agents Chemother. 61, e01589–17 (2017). This resistome analysis of extensively drug-resistant Pseudomonas reveals the molecular epidemiology and a broad variety of resistance mechanisms.
17. Sader, H. S., Flamm, R. K., Streit, J. M., Doyle, T. B. & Castanheira, M. Antimicrobial activity of cefepime–zidebactam (WCK 5222) against clinical isolates of carbapenem-resistant Enterobacterales collected worldwide in 2018. ASM/ESCMID Drug Development Conference 2019 https://www.jmilabs.com/data/posters/ASM-ESCMID2019-cefepime-zidebactam-CRE.pdf (2019).
18. Castanheira, M., Doyle, T. B., Kantro, V., Mendes, R. E. & Shortridge, D. Meropenem–vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016–2018. Antimicrob. Agents Chemother. 64, 01951–19 (2019).
19. Dadashi, M. et al. Frequency distribution, genotypes and the most prevalent sequence types of New Delhi metallo-beta-lactamase-producing Escherichia coli among clinical isolates around the world; a review. J. Glob. Antimicrob. Resist. 19, 284–293 (2019).
20. Bush, K. & Bradford, P. A. Epidemiology of beta-lactamase-producing pathogens. Clin. Microbiol. Rev. 33, e00047-19 (2020).
21. Grundmann, H. et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect. Dis. 17, 153–163 (2017).
22. Mueller, L. et al. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime–avibactam and exhibiting reduced carbapenemase activity. Antimicrob. Agents Chemother. 63, 01111–01119 (2019).
23. Giddins, M. J. et al. Successive emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in bla(KPC-2)-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob. Agents Chemother. 62, e02101–e02117 (2018).
24. Palzkill, T. Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC β-lactamases. Front. Mol. Biosci. 5, 16–16 (2018).
25. Chetri, S. et al. AcrAB-TolC efflux pump system plays a role in carbapenem non-susceptibility in Escherichia coli. BMC Microbiol. 19, 210 (2019).
26. Alm, R. A., Johnstone, M. R. & Lahiri, S. D. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J. Antimicrob. Chemother. 70, 1420–1428 (2015).
27. Galani, I. et al. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect. Dis. 19, 167 (2019).
28. Capone, A. et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin. Microbiol. Infect. 19, E23–E30 (2013).
29. Andrey, D. O. et al. An emerging clone, Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae Sequence Type 16, associated with high mortality rates in a CC258-endemic setting. Clin. Infect. Dis. 10.1093/cid/ciz1095 (2019).
30. David, S. et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat. Microbiol. 4, 1919–1929 (2019).
31. Pérez-Vázquez, M. et al. Emergence of NDM-producing Klebsiella pneumoniae and Escherichia coli in Spain: phylogeny, resistome, virulence and plasmids encoding blaNDM-like genes as determined by WGS. J. Antimicrob. Chemother. 74, 3489–3496 (2019).
32. Krajnc, A., Lang, P. A., Panduwawala, T. D., Brem, J. & Schofield, C. J. Will morphing boron-based inhibitors beat the β-lactamases? Curr. Opin. Chem. Biol. 50, 101–110 (2019).
33. Tehrani, K. H. M. E. & Martin, N. I. β-lactam/β-lactamase inhibitor combinations: an update. MedChemComm 9, 1439–1456 (2018).
34. Linciano, P., Cendron, L., Gianquinto, E., Spyrakis, F. & Tondi, D. Ten years with New Delhi metallo-beta-lactamase-1 (NDM-1): from structural insights to inhibitor design. ACS Infect. Dis. 5, 9–34 (2019).
35. Lomovskaya, O. et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 61, e01443-17 (2017).
36. Papp-Wallace, K. M. et al. Relebactam is a potent inhibitor of the KPC-2 β-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 62, e00174-18 (2018).
37. Karlowsky, J. A. et al. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J. Antimicrob. Chemother. 73, 1872–1879 (2018).
38. Balabanian, G., Rose, M., Manning, N., Landman, D. & Quale, J. Effect of porins and blaKPC expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance? Microb. Drug. Resist. 24, 877–881 (2018).
39. Moussa, S. H., Shapiro, A. B., McLeod, S. M. & A. Miller, A. A. Resistance to sulbactam–durlobactam in clinical isolates of Acinetobacter baumannii is rare and maps to PBP3. Acinetobacter Conference 2019 https://www.entasistx.com/application/files/3115/6959/0903/Moussa_SUL_Resistance_Acinetobacter2019_FINAL.pdf. (2019).
40. McLeod, S. M. et al. In vitro antibacterial activity of sulbactam–durlobactam (ETX2514) against 121 recent Acinetobacter baumannii isolates from patients in India. IDweek 2019 https://www.entasistx.com/application/files/2215/7115/9465/IDweek_2019_ETX2514_India_V11.pdf (2019).
41. Barnes, M. D. et al. targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio 10, e00159-19 (2019).
42. Livermore, D. M., Mushtaq, S., Warner, M. & Woodford, N. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J. Antimicrob. Chemother. 70, 3032–3041 (2015).
43. Mushtaq, S., Vickers, A., Woodford, N., Haldimann, A. & Livermore, D. M. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. J. Antimicrob. Chemother. 74, 953–960 (2018).
44. Okujava, R. et al. Activity of meropenem/nacubactam combination against Gram-negative clinical isolates: ROSCO global surveillance 2017. Open Forum Infect. Dis. 5, S416–S416 (2018).
45. Khan, Z., Iregui, A., Landman, D. & Quale, J. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres. J. Antimicrob. Chemother. 74, 2938–2942 (2019).
46. Thomson, K. S., AbdelGhani, S., Snyder, J. W. & Thomson, G. K. Activity of cefepime-zidebactam against multidrug-resistant (MDR) Gram-negative pathogens. Antibiotics 8, 32 (2019).
47. Krajnc, A. et al. Bicyclic boronate VNRX-5133 inhibits metallo- and serine-β-lactamases. J. Med. Chem. 62, 8544–8556 (2019).
48. Liu, B. et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections. J. Med. Chem. 10.1021/acs.jmedchem.9b01518 (2019).
49. Hackel, M. & Sahm, D. Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of β-lactamase-producing Enterobacteriaceae. ECCMID 2019 https://www.ihma.com/app/uploads/VenatoRx_P50_FEP-5133-BL_ECCMID-2019_FINAL.pdf (2019).
50. Hackel, M. & Sahm D. Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of Pseudomonas aeruginosa. ASM Microbe 2019 https://www.venatorx.com/wp-content/uploads/2019/07/ASMMicrobe2019-SUNDAY-AAR-722.pdf (2019).
51. Castanheira, M., Lindley, J., Huynh, H., Mendes, R. E. & Lomovskaya, O. Activity of novel β-lactamase inhibitor QPX7728 combined with β-lactam agents when tested against carbapenem-resistant Enterobacteriaceae (CRE) isolates. Open. Forum Infect. Dis. 6, S309–S309 (2019).
52. Mendes,R. E., Rhomberg, P. R., Watters, A. A., Castanheira, M., Flamm, R. K. In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 combination against a challenge set of Enterobacteriaceae pathogens carrying molecularly characterized β-lactamase genes. ECCMID 19 https://www.jmilabs.com/data/posters/ECCMID19-VNRX-7145-ceftibuten.pdf (2019).
53. John, K. J., Chatwin, C. L., Hamrick, J. C., Moeck, G. & Pevear, D. C. Rescue of ceftibuten activity by the oral β-lactamase inhibitor VNRX-7145 against Enterobacteriaceae expressing class A, C and/or D β-lactamases. ASM Microbe 2019 https://www.venatorx.com/wp-content/uploads/2019/07/ASMMicrobe2019-SUNDAY-AAR-719.pdf (2019).
54. M. Hackel & Sahm, D. In vitro activity of ceftibuten in combination with VNRX-7145 and comparators against 1,066 UTI isolates non-susceptible to amoxicillin–clavulanate and levofloxacin microbe. ASM Microbe 2019 https://www.venatorx.com/wp-content/uploads/2019/07/ASMMicrobe2019-SUNDAY-AAR-721.pdf (2019).
55. McLeod, S. et al. The antibacterial activity of sulbactam and the novel b-lactamase Inhibitor ETX2514 combined with imipenem or meropenem against recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. ASM Microbe 2017 https://www.entasistx.com/application/files/2815/1846/7310/McLeod-et-al-ASM-Microbe-2017-FRI-82.pdf (2017).
56. Duncan, L. R., Rhomberg, P. R., Mendes, R. E., Flamm, R. K. & Trias, J. Ceftibuten-avibactam activity against β-lactam-resistant Enterobacteriaceae clinical isolates. ASM Microbe 2019 https://www.jmilabs.com/data/posters/ASM-Microbe19-ceftibuten-avibactam.pdf (2019).
57. Papp-Wallace, K. M. et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-Lactam–β-lactamase inhibitor combination. Antimicrob. Agents Chemother. 63, e00105–e00119 (2019).
58. Gaibani, P. et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J. Antimicrob. Chemother. 73, 1525–1529 (2018).
59. Bush, K. Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother. 62, e01076-18 (2018). This study presents an extensive overview of β-lactamases including evolution and present situation.
60. Veeraraghavan, B. et al. Newer β-lactam/β-lactamase inhibitor for multidrug-resistant gram-negative infections: challenges, implications and surveillance strategy for India. Indian J. Med. Microbiol. 36, 334–343 (2018).
61. Negash, K. H., Norris, J. K. S. & Hodgkinson, J. T. Siderophore–antibiotic conjugate design: new drugs for bad bugs? Molecules 24, 3314 (2019).
62. Ito, A. et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 60, 7396–7401 (2016).
63. Jacobs, M. R. et al. ARGONAUT-I: Activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob. Agents Chemother. 63, e01801–e01818 (2018).
64. Karlowsky, J. A. et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int. J. Antimicrob. Agents 53, 456–466 (2019).
65. Kazmierczak, K. M. et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 study). Int. J. Antimicrob. Agents 53, 177–184 (2019).
66. Echols, R., Ariyasu, M. & Nagata, T. D. Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance. Clin. Infect. Dis. 69, S559–S564 (2019).
67. Food and Drug Administration. FDA briefing document: meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) https://www.fda.gov/media/131703/download (2019).
68. Blais, J. et al. In vitro activity of LYS228, a novel monobactam antibiotic, against multidrug-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 62, e00552–18 (2018).
69. Dean, C. R. et al. Mode of action of the monobactam LYS228 and mechanisms decreasing in vitro susceptibility in escherichia coli and Klebsiella pneumoniae. Antimicrob. Agents Chemother. 62, e01200–e01218 (2018).
70. Dunne, M. Huband, M., Flamm, R., Aronin, S. & Puttagunta, S. Prediction of sulopenem activity against Enterobacteriaceae using ertapenem as a surrogate. ASM Microbe 2018 https://d1io3yog0oux5.cloudfront.net/_1af31c1063e9451129263f05d42bc5fa/iterumtx/db/395/2664/pdf/ASM+2018_Ertapenem+surrogate.Final.pdf (2018).
71. Iterum Therapeutics. Press release 10. 12. 2019: Iterum Therapeutics announces topline results from phase III clinical trial of oral and IV sulopenem for the treatment of complicated intra-abdominal infections. https://www.globenewswire.com/news-release/2019/12/10/1958907/0/en/Iterum-Therapeutics-Announces-Topline-Results-from-Phase-3-Clinical-Trial-of-Oral-and-IV-Sulopenem-for-the-Treatment-of-Complicated-Intra-abdominal-Infections.html (2019).
72. Karlowsky, J. A. et al. In vitro activity of sulopenem, an oral penem, against urinary isolates of escherichia coli. Antimicrob. Agents Chemother. 63, e01832-18 (2018).
73. McEntee, L. et al. Pharmacodynamics of tebipenem: new options for oral treatment of multidrug-resistant Gram-negative infections. Antimicrob. Agents Chemother. 63, e00603–e00619 (2019).
74. Richter, S. E. et al. Risk factors for development of carbapenem resistance among gram-negative rods. Open Forum Infect. Dis. 6, ofz027 (2019).
75. Thaker, M., Spanogiannopoulos, P. & Wright, G. D. The tetracycline resistome. Cell Mol. Life Sci. 67, 419–431 (2010). This study presents an overview of structure, mechanism and regulation of the genes and proteins associated with tetracycline resistance.
76. Villa, L., Feudi, C., Fortini, D., García-Fernández, A. & Carattoli, A. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance. Antimicrob. Agents Chemother. 58, 1707–1712 (2014).
77. Park, J. et al. Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes. Nat. Chem. Biol. 13, 730–736 (2017).
78. Sun, J. et al. Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat. Microbiol. 4, 1457–1464 (2019).
79. Grossman, T. H. Tetracycline antibiotics and resistance. Cold Spring Harb. Perspect. Med. 6, a025387–a025387 (2016).
80. He, T. et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat. Microbiol. 4, 1450–1456 (2019).
81. Zhang, Y., Lin, X. & Bush, K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J. Antibiotics 69, 600–604 (2016).
82. Pfaller, M. A., Rhomberg, P. R., Huband, M. D. & Flamm, R. K. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn. Microbiol. Infect. Dis. 91, 179–183 (2018).
83. Kaminishi, T. et al. Third-generation tetracycline KBP-7072 exploit reveal a new potential primary tetracycline binding pocket. Preprint at 10.1101/508218 (2018).
84. Yang, F., Wang, Y., Wang, P., Hong, M. & Benn, V. Multiple ascending dose safety, tolerability, and pharmacokinetics of KBP-7072, a novel third-generation tetracycline. Open For. Infect. Dis. 4, S291–S291 (2017).
85. Huband, M. D. et al. Activity of KBP-7072 against recent and molecularly characterized Acinetobacter baumannii isolates. ASM/ESCMID Drug Development Conference 2019 https://www.jmilabs.com/data/posters/ASM-ESCMID2019-KBP-7072-Acinetobacter.pdf (JMI Labs, 2019).
86. Falagas, M. E. et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int. J. Antimicrob. Agents 52, 269–271 (2018).
87. Fyfe, C., LeBlanc, G., Close, B. & Newman J. TP-6076 is active against carbapenem- and polymyxin-resistant Enterobacteriaceae and Acinetobacter baumannii isolates. ECCMID 2017 https://www.escmid.org/typo3conf/ext/escmid_solr/Resources/Images/icn_abstract-hover.png (Vienna, 2017).
88. Sun, C. et al. TP-6076, a fully synthetic tetracycline antibacterial agent, is highly potent against a broad range of pathogens, including carbapenem-resistant Enterobacteriaceae. ASM Microbe 2017 https://www.tphase.com/wp-content/uploads/2019/04/Sun-S_ASM_2017_SUN-332-poster_6076-SAR_FINAL.pdf (2017).
89. Tsai, L. & Moore, A. Safety, tolerability, and pharmacokinetics of multiple doses of TP-6076, a novel, fully synthetic tetracycline, in a phase I study. Open Forum Infect. Dis. 5, S420–S420 (2018).
90. Grossman, T. H. et al. Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens. mSphere 2, e00004–e00017 (2017).
91. Aruhomukama, D., Sserwadda, I. & Mboowa, G. Investigating colistin drug resistance: the role of high-throughput sequencing and bioinformatics. F1000Research 8, 150–150 (2019).
92. Brown, P. et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect. Dis. 5, 1645–1656 (2019).
93. Corbett, D. et al. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob. Agents Chemother. 61, e00200–e00217 (2017).
94. Fleischmann, W. A., Greenwood-Quaintance, K. E. & Patel, R. In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug resistant aerobic Gram-negative bacilli. Antimicrob. Agents Chemother. 10.1128/AAC.01711-19 (2019).
95. Serio, A., Keepers, T., Andrews, L. & Krause, K. Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation. EcoSal Plus https://doi.org/10.1128/ecosalplus.ESP-0002-2018 (2018).
96. Livermore, D. M. et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66, 48–53 (2010).
97. Juhas, M. et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J. Antimicrob. Chemother. 74, 944–952 (2019).
98. Hunter, J. E., Hart, C. A., Shelley, J. C., Walton, J. R. & Bennett, M. Human isolates of apramycin-resistant Escherichia coli which contain the genes for the AAC(3)IV enzyme. Epidemiol. Infect. 110, 253–259 (1993).
99. Yang, Y., Hu, F. & Zhu, D. evaluation of contezolid activity to anaerobic and gram-positive-cocci isolates from a phase III acute bacterial skin and skin structure infection clinical trial (MRX-I-06). Open Forum Infect. Dis. 6, S315–S315 (2019).
100. Flamm, R. K., Rhomberg, P. R. & Sader, H. S. In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrob. Agents Chemother. 61, e01230–17 (2017).
101. Fisher, C. et al. Activity of TNP-2092 against biofilms formed by prosthetic joint infection-associated staphylococci. Open Forum Infect. Dis. 6, S313–S313 (2019).
102. Yao, J., Maxwell, J. B. & Rock, C. O. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J. Biol. Chem. 288, 36261–36271 (2013).
103. Schiebel, J. et al. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20, 802–813 (2012).
104. Hawser, S. et al. Activity of debio 1452 against Staphylococcus spp. collected in 2013/2014. ECCMID 2016 https://www.ihma.com/app/uploads/P139_POSTER_Debiopharm_IHMA_ECCMID_2016_v1-final.pdf (2016).
105. Menetrey, A. et al. Bone and joint tissue penetration of the Staphylococcus-selective antibiotic afabicin in patients undergoing elective hip replacement surgery. Antimicrob. Agents Chemother. 63, e01669-18 (2019).
106. Escaich, S. et al. The MUT056399 Inhibitor of FabI is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 55, 4692–4697 (2011).
107. Kaul, M. et al. TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 59, 4845 (2015).
108. Kaul, M., Mark, L., Parhi, A. K., LaVoie, E. J. & Pilch, D. S. Combining the FtsZ-targeting prodrug TXA709 and the cephalosporin cefdinir confers synergy and reduces the frequency of resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 60, 4290 (2016).
109. Basarab, G. S. et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci. Rep. 5, 11827–11827 (2015).
110. Taylor, S. N. et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase II, randomized, dose-ranging, single-oral dose evaluation. Clin. Infect. Dis. 67, 504–512 (2018).
111. Negash, K. et al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica 46, 683–702 (2016).
112. Flamm, R. K., Farrell, D. J., Rhomberg, P. R., Scangarella-Oman, N. E. & Sader, H. S. Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 61, e00468–17 (2017).
113. Bisacchi, G. S. & Manchester, J. I. A new-class antibacterial — almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors DNA gyrase topoisomerase IV. ACS Infect. Dis. 1, 4–41 (2015). This study presents insights into the historical attempts to discover and develop ATPase inhibitors of gyrase and topo IV as new-class antibacterial agents with broad-spectrum potential.
114. Brown-Elliott, B. A., Rubio, A. & Wallace, R. J. Jr. In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria. Antimicrob. Agents Chemother. 62, e01503–e01518 (2018).
115. Food & Drug Administration. Drug approval package: XENLENTA https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,211673Orig1s000TOC.cfm (2020).
116. Cho, J. C., Crotty, M. P. & Pardo, J. Ridinilazole: a novel antimicrobial for Clostridium difficile infection. Ann. Gastroenterol. 32, 134–140 (2019).
117. Bassères, E. et al. Understanding the Mechanism of Action of Ridinilazole (SMT19969), a Novel Treatment for Clostridium difficile. ECCMID 2016 https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=50079 (2016).
118. Khalaf, A. I. et al. Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity. J. Med. Chem. 47, 2133–2156 (2004).
119. Garey, K. W. et al. A Randomized, blinded, placebo- and vancomycin-controlled, first-in-human (FIH) study of the safety, pharmacokinetics (PK), and fecal microbiome effects of ACX-362E, a novel anti-clostridial DNA polymerase IIIC (polIIIC) inhibitor. Open Forum Infect. Dis. 6, S995–S996 (2019).
120. Green, L. S. et al. Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob. Agents Chemother. 53, 86–94 (2009).
121. Roberts, J. A. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect. Dis. 14, 498–509 (2014).
122. Livermore, D. M. The 2018 Garrod Lecture: preparing for the black swans of resistance. J. Antimicrob. Chemother. 73, 2907–2915 (2018).
123. Amaral, L., Martins, A., Spengler, G. & Molnar, J. Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front. Pharmacol. 4, 168 (2014).